{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T04:12:42Z","timestamp":1776312762050,"version":"3.50.1"},"reference-count":152,"publisher":"BMJ","issue":"9","license":[{"start":{"date-parts":[[2022,9,29]],"date-time":"2022-09-29T00:00:00Z","timestamp":1664409600000},"content-version":"unspecified","delay-in-days":28,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2022,8,20]]},"published-print":{"date-parts":[[2022,9]]},"abstract":"<jats:p>The broad activity of agents blocking the programmed cell death protein 1 and its ligand (the PD-(L)1 axis) revolutionized oncology, offering long-term benefit to patients and even curative responses for tumors that were once associated with dismal prognosis. However, only a minority of patients experience durable clinical benefit with immune checkpoint inhibitor monotherapy in most disease settings. Spurred by preclinical and correlative studies to understand mechanisms of non-response to the PD-(L)1 antagonists and by combination studies in animal tumor models, many drug development programs were designed to combine anti-PD-(L)1 with a variety of approved and investigational chemotherapies, tumor-targeted therapies, antiangiogenic therapies, and other immunotherapies. Several immunotherapy combinations improved survival outcomes in a variety of indications including melanoma, lung, kidney, and liver cancer, among others. This immunotherapy renaissance, however, has led to many combinations being advanced to late-stage development without definitive predictive biomarkers, limited phase I and phase II data, or clinical trial designs that are not optimized for demonstrating the unique attributes of immune-related antitumor activity\u2014for example, landmark progression-free survival and overall survival. The decision to activate a study at an individual site is investigator-driven, and generalized frameworks to evaluate the potential for phase III trials in immuno-oncology to yield positive data, particularly to increase the number of curative responses or otherwise advance the field have thus far been lacking. To assist in evaluating the potential value to patients and the immunotherapy field of phase III trials, the Society for Immunotherapy of Cancer (SITC) has developed a checklist for investigators, described in this manuscript. Although the checklist focuses on anti-PD-(L)1-based combinations, it may be applied to any regimen in which immune modulation is an important component of the antitumor effect.<\/jats:p>","DOI":"10.1136\/jitc-2022-005413","type":"journal-article","created":{"date-parts":[[2022,9,29]],"date-time":"2022-09-29T11:35:35Z","timestamp":1664451335000},"page":"e005413","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":15,"title":["Maximizing the value of phase III trials in immuno-oncology: A checklist from the Society for Immunotherapy of Cancer (SITC)"],"prefix":"10.1136","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3901-9924","authenticated-orcid":false,"given":"Michael B","family":"Atkins","sequence":"first","affiliation":[{"name":"Georgetown Lombardi Comprehensive Cancer Center, Washington, District of Columbia, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hamzah","family":"Abu-Sbeih","sequence":"additional","affiliation":[{"name":"University of Missouri Kansas City, Kansas City, Missouri, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8322-475X","authenticated-orcid":false,"given":"Paolo A","family":"Ascierto","sequence":"additional","affiliation":[{"name":"Istituto Nazionale Tumori IRCCS Fondazione \"G Pascale\", Napoli, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael R","family":"Bishop","sequence":"additional","affiliation":[{"name":"The David and Etta Jonas Center for Cellular Therapy, University of Chicago, Chicago, Illinois, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5085-3579","authenticated-orcid":false,"given":"Daniel S","family":"Chen","sequence":"additional","affiliation":[{"name":"Engenuity Life Sciences, Burlingame, California, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Madhav","family":"Dhodapkar","sequence":"additional","affiliation":[{"name":"Center for Cancer Immunology, Winship Cancer Institute at Emory University, Atlanta, Georgia, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7694-0731","authenticated-orcid":false,"given":"Leisha A","family":"Emens","sequence":"additional","affiliation":[{"name":"UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8132-7069","authenticated-orcid":false,"given":"Marc S","family":"Ernstoff","sequence":"additional","affiliation":[{"name":"DCTD\/DTP-IOB, ImmunoOncology Branch, NCI, Bethesda, Maryland, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6605-2071","authenticated-orcid":false,"given":"Robert L","family":"Ferris","sequence":"additional","affiliation":[{"name":"UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0806-2535","authenticated-orcid":false,"given":"Tim F","family":"Greten","sequence":"additional","affiliation":[{"name":"Gastrointestinal Malignancies Section, National Cancer Institue CCR Liver Program, Bethesda, Maryland, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6569-2912","authenticated-orcid":false,"given":"James L","family":"Gulley","sequence":"additional","affiliation":[{"name":"Center for Immuno-Oncology, National Cancer Institute, Bethesda, Maryland, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roy S","family":"Herbst","sequence":"additional","affiliation":[{"name":"Yale Cancer Center, New Haven, Connecticut, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rachel W","family":"Humphrey","sequence":"additional","affiliation":[{"name":"Normunity, Inc, South San Francisco, California, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James","family":"Larkin","sequence":"additional","affiliation":[{"name":"Royal Marsden Hospital, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5248-4356","authenticated-orcid":false,"given":"Kim A","family":"Margolin","sequence":"additional","affiliation":[{"name":"St. John's Cancer Institute, Santa Monica, California, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4043-3279","authenticated-orcid":false,"given":"Luca","family":"Mazzarella","sequence":"additional","affiliation":[{"name":"Experimental Oncology, New Drug Development, European Instititue of Oncology IRCCS, Milan, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suresh S","family":"Ramalingam","sequence":"additional","affiliation":[{"name":"Winship Cancer Institute of Emory University, Atlanta, Georgia, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2428-6109","authenticated-orcid":false,"given":"Meredith M","family":"Regan","sequence":"additional","affiliation":[{"name":"Dana-Farber\/Harvard Cancer Center, Boston, Massachusetts, USA"},{"name":"Harvard Medical School, Boston, Massachusetts, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian I","family":"Rini","sequence":"additional","affiliation":[{"name":"Ingram Cancer Center, Nashville, Tennessee, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4137-9662","authenticated-orcid":false,"given":"Mario","family":"Sznol","sequence":"additional","affiliation":[{"name":"Yale School of Medicine, New Haven, Connecticut, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2022,9,29]]},"reference":[{"key":"2025100302064778000_10.9.e005413.1","doi-asserted-by":"crossref","first-page":"3350","DOI":"10.1200\/JCO.19.00345","article-title":"Treatment-Free survival: a novel outcome measure of the effects of immune checkpoint Inhibition-A pooled analysis of patients with advanced melanoma","volume":"37","author":"Regan","year":"2019","journal-title":"J Clin Oncol"},{"key":"2025100302064778000_10.9.e005413.2","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-017-0241-6"},{"key":"2025100302064778000_10.9.e005413.3","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.jtho.2020.09.015","article-title":"Long-Term overall survival from KEYNOTE-021 cohort G: pemetrexed and carboplatin with or without pembrolizumab as first-line therapy for advanced Nonsquamous NSCLC","volume":"16","author":"Awad","year":"2021","journal-title":"J Thorac Oncol"},{"key":"2025100302064778000_10.9.e005413.4","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-019-0594-0"},{"key":"2025100302064778000_10.9.e005413.5","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.00131"},{"key":"2025100302064778000_10.9.e005413.6","doi-asserted-by":"publisher","DOI":"10.20892\/j.issn.2095-3941.2016.0015"},{"key":"2025100302064778000_10.9.e005413.7","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1001\/jamaoncol.2019.2186","article-title":"Appraising the tail of the survival curve in the era of PD-1\/PD-L1 checkpoint blockade","volume":"5","author":"Zimmermann","year":"2019","journal-title":"JAMA Oncol"},{"key":"2025100302064778000_10.9.e005413.8","doi-asserted-by":"publisher","DOI":"10.1126\/science.959840"},{"key":"2025100302064778000_10.9.e005413.9","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-019-1730-1"},{"key":"2025100302064778000_10.9.e005413.10","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2019.12.011"},{"key":"2025100302064778000_10.9.e005413.11","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s40425-017-0218-5","article-title":"Combination immunotherapy: a road map","volume":"5","author":"Ott","year":"2017","journal-title":"j. immunotherapy cancer"},{"key":"2025100302064778000_10.9.e005413.12","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2019.20833","article-title":"Assessment of clinical activity of PD-1 checkpoint inhibitor combination therapies reported in clinical trials","volume":"3","author":"Schmidt","year":"2020","journal-title":"JAMA Netw Open"},{"key":"2025100302064778000_10.9.e005413.13","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-002459"},{"key":"2025100302064778000_10.9.e005413.14","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1915745"},{"key":"2025100302064778000_10.9.e005413.15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1302369"},{"key":"2025100302064778000_10.9.e005413.16","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1810865"},{"key":"2025100302064778000_10.9.e005413.17","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1816714"},{"key":"2025100302064778000_10.9.e005413.18","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)32531-9"},{"key":"2025100302064778000_10.9.e005413.19","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdy551"},{"key":"2025100302064778000_10.9.e005413.20","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.canlet.2018.08.028","article-title":"Immunogenic cell death in anticancer chemotherapy and its impact on clinical studies","volume":"438","author":"Wang","year":"2018","journal-title":"Cancer Lett"},{"key":"2025100302064778000_10.9.e005413.21","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-16-0881"},{"key":"2025100302064778000_10.9.e005413.22","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-10-0118"},{"key":"2025100302064778000_10.9.e005413.23","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.phrs.2018.08.019","article-title":"Immunomodulatory effects of BRAF and MEK inhibitors: implications for melanoma therapy","volume":"136","author":"Kuske","year":"2018","journal-title":"Pharmacol Res"},{"key":"2025100302064778000_10.9.e005413.24","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.22.1507"},{"key":"2025100302064778000_10.9.e005413.25","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms12624","article-title":"Atezolizumab in combination with bevacizumab enhances antigen-specific T-cell migration in metastatic renal cell carcinoma","volume":"7","author":"Wallin","year":"2016","journal-title":"Nat Commun"},{"key":"2025100302064778000_10.9.e005413.26","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-002627","article-title":"Development of preclinical and clinical models for immune-related adverse events following checkpoint immunotherapy: a perspective from SITC and AACR","volume":"9","author":"Bayless","year":"2021","journal-title":"J Immunother Cancer"},{"key":"2025100302064778000_10.9.e005413.27","doi-asserted-by":"crossref","unstructured":"Zloza A , Karolina Palucka A , Coussens LM , et al . Workshop on challenges, insights, and future directions for mouse and humanized models in cancer immunology and immunotherapy: a report from the associated programs of the 2016 annual meeting for the Society for immunotherapy of cancer. J Immunother Cancer 2017;5.doi:10.1186\/s40425-017-0278-6","DOI":"10.1186\/s40425-017-0278-6"},{"key":"2025100302064778000_10.9.e005413.28","doi-asserted-by":"publisher","DOI":"10.1038\/nbt.2786"},{"key":"2025100302064778000_10.9.e005413.29","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1097\/MJT.0b013e318269198f","article-title":"Pharmaceutical R&D performance by firm size: approval success rates and economic returns","volume":"21","author":"DiMasi","year":"2014","journal-title":"Am J Ther"},{"key":"2025100302064778000_10.9.e005413.30","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.194"},{"key":"2025100302064778000_10.9.e005413.31","unstructured":"AW L , Siah KW , Wong CH . Machine learning with statistical imputation for predicting drug approvals. SSRN 2018."},{"key":"2025100302064778000_10.9.e005413.32","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.drudis.2019.12.014","article-title":"Key indicators of phase transition for clinical trials through machine learning","volume":"25","author":"Feijoo","year":"2020","journal-title":"Drug Discov Today"},{"key":"2025100302064778000_10.9.e005413.33","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1001\/jamainternmed.2018.3931","article-title":"Estimated costs of pivotal trials for novel therapeutic agents Approved by the US food and drug administration, 2015-2016","volume":"178","author":"Moore","year":"2018","journal-title":"JAMA Intern Med"},{"key":"2025100302064778000_10.9.e005413.34","doi-asserted-by":"publisher","DOI":"10.1038\/nrd3681"},{"key":"2025100302064778000_10.9.e005413.35","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1056\/NEJMp2109826","article-title":"The Drug-Dosing Conundrum in Oncology - When Less Is More","volume":"385","author":"Shah","year":"2021","journal-title":"N Engl J Med"},{"key":"2025100302064778000_10.9.e005413.36","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.conctc.2018.08.001","article-title":"Factors associated with clinical trials that fail and opportunities for improving the likelihood of success: a review","volume":"11","author":"Fogel","year":"2018","journal-title":"Contemp Clin Trials Commun"},{"key":"2025100302064778000_10.9.e005413.37","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.ctrv.2016.10.009","article-title":"Factors associated with failure of oncology drugs in late-stage clinical development: a systematic review","volume":"52","author":"Jardim","year":"2017","journal-title":"Cancer Treat Rev"},{"key":"2025100302064778000_10.9.e005413.38","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2013.282542"},{"key":"2025100302064778000_10.9.e005413.39","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1159\/000496119","article-title":"Value and values in cancer care. assessing the benefit of treatment in patients with advanced cancer","volume":"42","author":"Schildmann","year":"2019","journal-title":"Oncol Res Treat"},{"key":"2025100302064778000_10.9.e005413.40","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/s11899-016-0333-2","article-title":"Value based care and patient-centered care: divergent or complementary?","volume":"11","author":"Tseng","year":"2016","journal-title":"Curr Hematol Malig Rep"},{"key":"2025100302064778000_10.9.e005413.41","doi-asserted-by":"publisher","DOI":"10.1093\/biostatistics\/kxx069"},{"key":"2025100302064778000_10.9.e005413.42","doi-asserted-by":"crossref","DOI":"10.1016\/j.jcpo.2021.100301","article-title":"Patient perspectives of value of delayed disease progression on imaging (imaging PFS). A treatment trade-off experiment","volume":"30","author":"Robinson","year":"2021","journal-title":"J Cancer Policy"},{"key":"2025100302064778000_10.9.e005413.43","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1003466"},{"key":"2025100302064778000_10.9.e005413.44","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1056\/NEJMoa1001294","article-title":"Sipuleucel-T immunotherapy for castration-resistant prostate cancer","volume":"363","author":"Kantoff","year":"2010","journal-title":"N Engl J Med Overseas Ed"},{"key":"2025100302064778000_10.9.e005413.45","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1056\/NEJMoa2103485","article-title":"Overall survival benefit with Tebentafusp in metastatic uveal melanoma","volume":"385","author":"Nathan","year":"2021","journal-title":"N Engl J Med Overseas Ed"},{"key":"2025100302064778000_10.9.e005413.46","doi-asserted-by":"publisher","DOI":"10.1038\/74704"},{"key":"2025100302064778000_10.9.e005413.47","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2013.07.012"},{"key":"2025100302064778000_10.9.e005413.48","doi-asserted-by":"publisher","DOI":"10.1038\/ni1102-991"},{"key":"2025100302064778000_10.9.e005413.49","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-18-0367"},{"key":"2025100302064778000_10.9.e005413.50","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3239"},{"key":"2025100302064778000_10.9.e005413.51","doi-asserted-by":"publisher","DOI":"10.1038\/nature13954"},{"key":"2025100302064778000_10.9.e005413.52","doi-asserted-by":"publisher","DOI":"10.1038\/nature19330"},{"key":"2025100302064778000_10.9.e005413.53","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.immuni.2018.12.021","article-title":"Intratumoral Tcf1+PD-1+CD8+ T Cells with Stem-like Properties Promote Tumor Control in Response to Vaccination and Checkpoint Blockade Immunotherapy","volume":"50","author":"Siddiqui","year":"2019","journal-title":"Immunity"},{"key":"2025100302064778000_10.9.e005413.54","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-019-0312-6"},{"key":"2025100302064778000_10.9.e005413.55","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.192461099"},{"key":"2025100302064778000_10.9.e005413.56","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-03-3259"},{"key":"2025100302064778000_10.9.e005413.57","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1158\/0008-5472.1089.65.3","article-title":"Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity","volume":"65","author":"Hirano","year":"2005","journal-title":"Cancer Res"},{"key":"2025100302064778000_10.9.e005413.58","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30516-8"},{"key":"2025100302064778000_10.9.e005413.59","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-019-0382-x"},{"key":"2025100302064778000_10.9.e005413.60","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1200690"},{"key":"2025100302064778000_10.9.e005413.61","doi-asserted-by":"publisher","DOI":"10.1038\/nature14011"},{"key":"2025100302064778000_10.9.e005413.62","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-019-1922-8"},{"key":"2025100302064778000_10.9.e005413.63","doi-asserted-by":"publisher","DOI":"10.1172\/JCI91190"},{"key":"2025100302064778000_10.9.e005413.64","doi-asserted-by":"publisher","DOI":"10.1038\/nature22079"},{"key":"2025100302064778000_10.9.e005413.65","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/978-3-030-38862-1_6","article-title":"The paradox of cancer immune exclusion: immune oncology next frontier","volume":"180","author":"Pai","year":"2020","journal-title":"Cancer Treat Res"},{"key":"2025100302064778000_10.9.e005413.66","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2016.02.065"},{"key":"2025100302064778000_10.9.e005413.67","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-019-0780-0"},{"key":"2025100302064778000_10.9.e005413.68","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-14290-4"},{"key":"2025100302064778000_10.9.e005413.69","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2021.39.15_suppl.9503"},{"key":"2025100302064778000_10.9.e005413.70","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1821218116"},{"key":"2025100302064778000_10.9.e005413.71","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1038\/s41573-018-0007-y","article-title":"Approaches to treat immune hot, altered and cold tumours with combination immunotherapies","volume":"18","author":"Galon","year":"2019","journal-title":"Nat Rev Drug Discov"},{"key":"2025100302064778000_10.9.e005413.72","doi-asserted-by":"publisher","DOI":"10.1038\/nature21349"},{"key":"2025100302064778000_10.9.e005413.73","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdr608"},{"key":"2025100302064778000_10.9.e005413.74","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.1016\/j.cell.2017.11.009","article-title":"Combination cancer therapy can confer benefit via Patient-to-Patient variability without drug additivity or synergy","volume":"171","author":"Palmer","year":"2017","journal-title":"Cell"},{"key":"2025100302064778000_10.9.e005413.75","doi-asserted-by":"crossref","first-page":"S1172","DOI":"10.1016\/j.annonc.2020.08.2273","article-title":"LBA43 Spartalizumab plus dabrafenib and trametinib (Sparta-DabTram) in patients (PTS) with previously untreated BRAF V600\u2013mutant unresectable or metastatic melanoma: results from the randomized Part 3 of the phase III COMBI-i trial","volume":"31","author":"Nathan","year":"2020","journal-title":"Annals of Oncology"},{"key":"2025100302064778000_10.9.e005413.76","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1016\/S0140-6736(20)30934-X","article-title":"Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAFV600 mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial","volume":"395","author":"Gutzmer","year":"2020","journal-title":"The Lancet"},{"key":"2025100302064778000_10.9.e005413.77","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djq310"},{"key":"2025100302064778000_10.9.e005413.78","doi-asserted-by":"publisher","DOI":"10.1186\/2051-1426-1-18"},{"key":"2025100302064778000_10.9.e005413.79","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-15-0260"},{"key":"2025100302064778000_10.9.e005413.80","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.yrtph.2015.07.022","article-title":"Impact analysis of ICH S9 on non-clinical development of anticancer drugs","volume":"73","author":"Bonelli","year":"2015","journal-title":"Regul Toxicol Pharmacol"},{"key":"2025100302064778000_10.9.e005413.81","unstructured":"Food and Drug Administration . Guidance for industry: codevelopment of two or more new investigational drugs for use in combination; 2013."},{"key":"2025100302064778000_10.9.e005413.82","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3245"},{"key":"2025100302064778000_10.9.e005413.83","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.88328","article-title":"Lack of immunoediting in murine pancreatic cancer reversed with neoantigen","volume":"1","author":"Evans","year":"2016","journal-title":"JCI Insight"},{"key":"2025100302064778000_10.9.e005413.84","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1613601113"},{"key":"2025100302064778000_10.9.e005413.85","doi-asserted-by":"publisher","DOI":"10.1038\/s41587-020-0613-1"},{"key":"2025100302064778000_10.9.e005413.86","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-16-1260"},{"key":"2025100302064778000_10.9.e005413.87","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-18-0874"},{"key":"2025100302064778000_10.9.e005413.88","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2018.03.015"},{"key":"2025100302064778000_10.9.e005413.89","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-016-0200-7"},{"key":"2025100302064778000_10.9.e005413.90","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.672916","article-title":"Correlation between early endpoints and overall survival in non-small-cell lung cancer: a Trial-Level meta-analysis","volume":"11","author":"Shameer","year":"2021","journal-title":"Front Oncol"},{"key":"2025100302064778000_10.9.e005413.91","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2019-000398","article-title":"Defining tumor resistance to PD-1 pathway blockade: recommendations from the first meeting of the SITC immunotherapy resistance Taskforce","volume":"8","author":"Kluger","year":"2020","journal-title":"J Immunother Cancer"},{"key":"2025100302064778000_10.9.e005413.92","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1504030"},{"key":"2025100302064778000_10.9.e005413.93","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1816047"},{"key":"2025100302064778000_10.9.e005413.94","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2109970"},{"key":"2025100302064778000_10.9.e005413.95","doi-asserted-by":"crossref","first-page":"v611","DOI":"10.1093\/annonc\/mdx440.011","article-title":"Efficacy of BMS-986016, a monoclonal antibody that targets lymphocyte activation gene-3 (LAG-3), in combination with nivolumab in PTS with melanoma who progressed during prior anti\u2013PD-1\/PD-L1 therapy (MEL prior io) in all-comer and biomarker-enriched populations","volume":"28","author":"Ascierto","year":"2017","journal-title":"Annals of Oncology"},{"key":"2025100302064778000_10.9.e005413.96","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1016\/S1470-2045(19)30274-8","article-title":"Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301\/KEYNOTE-252): a phase 3, randomised, double-blind study","volume":"20","author":"Long","year":"2019","journal-title":"Lancet Oncol"},{"key":"2025100302064778000_10.9.e005413.97","doi-asserted-by":"crossref","first-page":"2165","DOI":"10.2217\/fon-2020-0351","article-title":"Bempegaldesleukin plus nivolumab in untreated, unresectable or metastatic melanoma: phase III pivot io 001 study design","volume":"16","author":"Khushalani","year":"2020","journal-title":"Future Oncol"},{"key":"2025100302064778000_10.9.e005413.98","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-06-1488"},{"key":"2025100302064778000_10.9.e005413.99","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2008.10.029"},{"key":"2025100302064778000_10.9.e005413.100","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djr218"},{"key":"2025100302064778000_10.9.e005413.101","doi-asserted-by":"crossref","DOI":"10.1016\/S1470-2045(22)00226-1","article-title":"Tiragolumab plus atezolizumab versus placebo plus atezolizumab as a first-line treatment for PD-L1-selected non-small-cell lung cancer (CITYSCAPE): primary and follow-up analyses of a randomised, double-blind, phase 2 study","volume":"23","author":"Cho","year":"2022","journal-title":"Lancet Oncol"},{"key":"2025100302064778000_10.9.e005413.102","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djv156","article-title":"Milestone survival: a potential intermediate endpoint for immune checkpoint inhibitors","volume":"107","author":"Chen","year":"2015","journal-title":"J Natl Cancer Inst"},{"key":"2025100302064778000_10.9.e005413.103","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1809615"},{"key":"2025100302064778000_10.9.e005413.104","doi-asserted-by":"crossref","first-page":"eS22","DOI":"10.1016\/S0007-4551(20)30283-6","article-title":"BIONIKK: a phase 2 biomarker driven trial with nivolumab and ipilimumab or VEGFR tyrosine kinase inhibitor (TKI) in na\u00efve metastatic kidney cancer","volume":"107","author":"Epaillard","year":"2020","journal-title":"Bull Cancer"},{"key":"2025100302064778000_10.9.e005413.105","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-020-07008-8"},{"key":"2025100302064778000_10.9.e005413.106","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2019-000475","article-title":"Master protocols in immuno-oncology: do novel drugs deserve novel designs?","volume":"8","author":"Mazzarella","year":"2020","journal-title":"J Immunother Cancer"},{"key":"2025100302064778000_10.9.e005413.107","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1200\/JCO.21.02229","article-title":"Long-Term outcomes with nivolumab plus ipilimumab or nivolumab alone versus ipilimumab in patients with advanced melanoma","volume":"40","author":"Wolchok","year":"2022","journal-title":"J Clin Oncol"},{"key":"2025100302064778000_10.9.e005413.108","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-21-2283"},{"key":"2025100302064778000_10.9.e005413.109","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1302338"},{"key":"2025100302064778000_10.9.e005413.110","doi-asserted-by":"crossref","first-page":"3851","DOI":"10.1200\/JCO.2016.72.1985","article-title":"Safety and efficacy of nivolumab in combination with ipilimumab in metastatic renal cell carcinoma: the CheckMate 016 study","volume":"35","author":"Hammers","year":"2017","journal-title":"J Clin Oncol"},{"key":"2025100302064778000_10.9.e005413.111","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.clgc.2021.04.007","article-title":"A phase I\/II study to assess the safety and efficacy of pazopanib and pembrolizumab combination therapy in patients with advanced renal cell carcinoma","volume":"19","author":"Chowdhury","year":"2021","journal-title":"Clin Genitourin Cancer"},{"key":"2025100302064778000_10.9.e005413.112","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30624-6"},{"key":"2025100302064778000_10.9.e005413.113","doi-asserted-by":"crossref","unstructured":"Atkins MB , Lee SJ , Chmielowski B . DREAMseq (doublet, randomized evaluation in advanced melanoma sequencing): a phase III trial\u2014ECOG-ACRIN EA6134. American Society of Clinical Oncology 2021.","DOI":"10.1200\/JCO.2021.39.36_suppl.356154"},{"key":"2025100302064778000_10.9.e005413.114","doi-asserted-by":"publisher","DOI":"10.1136\/esmoopen-2020-001079"},{"key":"2025100302064778000_10.9.e005413.115","doi-asserted-by":"crossref","DOI":"10.1186\/s12874-016-0117-3","article-title":"Predicting analysis times in randomized clinical trials with cancer immunotherapy","volume":"16","author":"Chen","year":"2016","journal-title":"BMC Med Res Methodol"},{"key":"2025100302064778000_10.9.e005413.116","doi-asserted-by":"publisher","DOI":"10.1093\/biomet\/68.1.316"},{"key":"2025100302064778000_10.9.e005413.117","doi-asserted-by":"crossref","first-page":"2042","DOI":"10.1177\/0962280217708681","article-title":"Landmark cure rate models with time-dependent covariates","volume":"26","author":"Shi","year":"2017","journal-title":"Stat Methods Med Res"},{"key":"2025100302064778000_10.9.e005413.118","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1586\/14737167.2015.1037835","article-title":"Treatment switching in oncology trials and the acceptability of adjustment methods","volume":"15","author":"Latimer","year":"2015","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"2025100302064778000_10.9.e005413.119","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1177\/0962280214557578","article-title":"Adjusting for treatment switching in randomised controlled trials - A simulation study and a simplified two-stage method","volume":"26","author":"Latimer","year":"2017","journal-title":"Stat Methods Med Res"},{"key":"2025100302064778000_10.9.e005413.120","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1177\/0962280216642264","article-title":"Assessing methods for dealing with treatment switching in clinical trials: a follow-up simulation study","volume":"27","author":"Latimer","year":"2018","journal-title":"Stat Methods Med Res"},{"key":"2025100302064778000_10.9.e005413.121","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.43.3946"},{"key":"2025100302064778000_10.9.e005413.122","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.jtho.2021.01.1616","article-title":"Biomarker discovery and validation: statistical considerations","volume":"16","author":"Ou","year":"2021","journal-title":"J Thorac Oncol"},{"key":"2025100302064778000_10.9.e005413.123","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-019-0589-x"},{"key":"2025100302064778000_10.9.e005413.124","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-15798-4"},{"key":"2025100302064778000_10.9.e005413.125","doi-asserted-by":"publisher","DOI":"10.1038\/s41379-021-00919-2"},{"key":"2025100302064778000_10.9.e005413.126","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1038\/s41571-019-0252-y","article-title":"Artificial intelligence in digital pathology - new tools for diagnosis and precision oncology","volume":"16","author":"Bera","year":"2019","journal-title":"Nat Rev Clin Oncol"},{"key":"2025100302064778000_10.9.e005413.127","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2018.1424675","article-title":"Circulating tumor DNA evaluated by next-generation sequencing is predictive of tumor response and prolonged clinical benefit with nivolumab in advanced non-small cell lung cancer","volume":"7","author":"Giroux Leprieur","year":"2018","journal-title":"Oncoimmunology"},{"key":"2025100302064778000_10.9.e005413.128","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1038\/s43018-020-0096-5","article-title":"Personalized circulating tumor DNA analysis as a predictive biomarker in solid tumor patients treated with pembrolizumab","volume":"1","author":"Bratman","year":"2020","journal-title":"Nat Cancer"},{"key":"2025100302064778000_10.9.e005413.129","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2018-5706"},{"key":"2025100302064778000_10.9.e005413.130","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1007\/s11307-020-01481-0","article-title":"Monitoring CD8a+ T Cell Responses to Radiotherapy and CTLA-4 Blockade Using [\n                  64\n               Cu]NOTA-CD8a PET Imaging","volume":"22","author":"Kristensen","year":"2020","journal-title":"Mol Imaging Biol"},{"key":"2025100302064778000_10.9.e005413.131","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13123083","article-title":"Response prediction and evaluation using PET in patients with solid tumors treated with immunotherapy","volume":"13","author":"Borm","year":"2021","journal-title":"Cancers"},{"key":"2025100302064778000_10.9.e005413.132","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1038\/s41586-021-03642-9","article-title":"ctDNA guiding adjuvant immunotherapy in urothelial carcinoma","volume":"595","author":"Powles","year":"2021","journal-title":"Nature"},{"key":"2025100302064778000_10.9.e005413.133","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-002955","article-title":"Pet\/Ct scan and biopsy-driven approach for safe anti-PD-1 therapy discontinuation in patients with advanced melanoma","volume":"9","author":"Gibney","year":"2021","journal-title":"J Immunother Cancer"},{"key":"2025100302064778000_10.9.e005413.134","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1093\/jnci\/djaa216","article-title":"Neoadjuvant immunotherapy for high-risk, resectable malignancies: scientific rationale and clinical challenges","volume":"113","author":"Krishnamoorthy","year":"2021","journal-title":"J Natl Cancer Inst"},{"key":"2025100302064778000_10.9.e005413.135","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1093\/annonc\/mdy218","article-title":"Pathologic features of response to neoadjuvant anti-PD-1 in resected non-small-cell lung carcinoma: a proposal for quantitative immune-related pathologic response criteria (irPRC)","volume":"29","author":"Cottrell","year":"2018","journal-title":"Ann Oncol"},{"key":"2025100302064778000_10.9.e005413.136","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1910549"},{"key":"2025100302064778000_10.9.e005413.137","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1056\/NEJMoa2112651","article-title":"Event-Free survival with pembrolizumab in early triple-negative breast cancer","volume":"386","author":"Schmid","year":"2022","journal-title":"N Engl J Med"},{"key":"2025100302064778000_10.9.e005413.138","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1016\/j.jval.2019.07.007","article-title":"Unmet medical need: an introduction to definitions and Stakeholder perceptions","volume":"22","author":"Vreman","year":"2019","journal-title":"Value Health"},{"key":"2025100302064778000_10.9.e005413.139","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1053\/j.seminoncol.2017.02.009","article-title":"What constitutes an \"unmet medical need\" in oncology? An empirical evaluation of author usage in the biomedical literature","volume":"44","author":"Lu","year":"2017","journal-title":"Semin Oncol"},{"key":"2025100302064778000_10.9.e005413.140","doi-asserted-by":"crossref","first-page":"TPS9597","DOI":"10.1200\/JCO.2018.36.15_suppl.TPS9597","article-title":"Combining ipilimumab (IPI) and nivolumab (nivo) in advanced melanoma following progression on a PD-1 inhibitor (SWOG S1616)","volume":"36","author":"Vanderwalde","year":"2018","journal-title":"Journal of Clinical Oncology"},{"key":"2025100302064778000_10.9.e005413.141","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2018.1.213"},{"key":"2025100302064778000_10.9.e005413.142","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1007\/s00277-017-3226-0","article-title":"Program death inhibitors in classical Hodgkin's lymphoma: a comprehensive review","volume":"97","author":"Dada","year":"2018","journal-title":"Ann Hematol"},{"key":"2025100302064778000_10.9.e005413.143","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1038\/s41571-020-0347-5","article-title":"T cell-engaging therapies - BiTEs and beyond","volume":"17","author":"Goebeler","year":"2020","journal-title":"Nat Rev Clin Oncol"},{"key":"2025100302064778000_10.9.e005413.144","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-017-0230-9"},{"key":"2025100302064778000_10.9.e005413.145","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2018.01740","article-title":"Car T cells in solid tumors: blueprints for building effective therapies","volume":"9","author":"Knochelmann","year":"2018","journal-title":"Front Immunol"},{"key":"2025100302064778000_10.9.e005413.146","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.718621","article-title":"Strategies to overcome failures in T-cell immunotherapies by targeting PI3K-\u03b4 and -\u03b3","volume":"12","author":"Chandrasekaran","year":"2021","journal-title":"Front Immunol"},{"key":"2025100302064778000_10.9.e005413.147","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-019-0184-6"},{"key":"2025100302064778000_10.9.e005413.148","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1093\/annonc\/mdw538","article-title":"Do contemporary randomized controlled trials meet ESMO thresholds for meaningful clinical benefit?","volume":"28","author":"Del Paggio","year":"2017","journal-title":"Annals of Oncology"},{"key":"2025100302064778000_10.9.e005413.149","doi-asserted-by":"crossref","unstructured":"Tibau A , Molto C , Ocana A , et al . Magnitude of clinical benefit of cancer drugs Approved by the US food and drug administration. 2018;110:486\u201392.doi:10.1093\/jnci\/djx232","DOI":"10.1093\/jnci\/djx232"},{"key":"2025100302064778000_10.9.e005413.150","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.31957"},{"key":"2025100302064778000_10.9.e005413.151","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1001\/jamainternmed.2018.4710","article-title":"Evaluating progression-free survival as a surrogate outcome for health-related quality of life in oncology: a systematic review and quantitative analysis","volume":"178","author":"Kovic","year":"2018","journal-title":"JAMA Intern Med"},{"key":"2025100302064778000_10.9.e005413.152","article-title":"Sequencing of Ipilimumab Plus Nivolumab and Encorafenib Plus Binimetinib for Untreated BRAF-Mutated Metastatic Melanoma (SECOMBIT): A Randomized, Three-Arm, Open-Label Phase II Trial","author":"Ascierto","year":"2022","journal-title":"J Clin Oncol"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2022-005413","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T09:07:03Z","timestamp":1759482423000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2022-005413"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":152,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2022,9,29]]},"published-print":{"date-parts":[[2022,9]]}},"alternative-id":["10.1136\/jitc-2022-005413"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2022-005413","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9]]}}}